Cargando…

Electrocardiographic assessments and cardiac events after fingolimod first dose – a comprehensive monitoring study

BACKGROUND: First dose observation for cardiac effects is required for fingolimod, but recommendations on the extent vary. This study aims to assess cardiac safety of fingolimod first dose. Individual bradyarrhythmic episodes were evaluated to assess the relevance of continuous electrocardiogram (EC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Limmroth, Volker, Ziemssen, Tjalf, Lang, Michael, Richter, Stephan, Wagner, Bert, Haas, Judith, Schmidt, Stephan, Gerbershagen, Kathrin, Lassek, Christoph, Klotz, Luisa, Hoffmann, Olaf, Albert, Christian, Schuh, Katrin, Baier-Ebert, Monika, Wendt, Guillaume, Schieb, Heinke, Hoyer, Susanne, Dechend, Ralf, Haverkamp, Wilhelm
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241949/ https://www.ncbi.nlm.nih.gov/pubmed/28100182 http://dx.doi.org/10.1186/s12883-016-0789-7

Ejemplares similares

A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose—Possible Predictors of Cardiac Outcomes
por: Limmroth, Volker, et al.
Publicado: (2020)

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit–Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany
por: Becker, Veit, et al.
Publicado: (2018)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration
por: Sehr, Tony, et al.
Publicado: (2020)

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease
por: Thomas, Katja, et al.
Publicado: (2014)

The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis
por: Inojosa, Hernan, et al.
Publicado: (2020)

Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation
por: Thomas, Katja, et al.
Publicado: (2017)

Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL
por: Alsop, Jonathan, et al.
Publicado: (2017)

Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

PTB-XL+, a comprehensive electrocardiographic feature dataset
por: Strodthoff, Nils, et al.
Publicado: (2023)

Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review
por: Ziemssen, T., et al.
Publicado: (2015)

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study
por: Butzkueven, Helmut, et al.
Publicado: (2022)

A randomized study to evaluate the effect of exercise on fatigue in people with relapsing–remitting multiple sclerosis treated with fingolimod
por: Mäurer, M, et al.
Publicado: (2018)

Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Fingolimod treatment promotes regulatory phenotype and function of B cells
por: Grützke, Berit, et al.
Publicado: (2015)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases
por: Schmidt, Stephan, et al.
Publicado: (2019)

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System—A Review
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Why Cognitive–Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice
por: Beste, Christian, et al.
Publicado: (2020)

Digital Innovation in Multiple Sclerosis Management
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Case Report: Human Bocavirus Associated Pneumonia as Cause of Acute Injury, Cologne, Germany
por: Krakau, Michael, et al.
Publicado: (2015)

Transparent Quality Optimization for Machine Learning-Based Regression in Neurology
por: Wendt, Karsten, et al.
Publicado: (2022)

Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Antidepressant activity of fingolimod in mice
por: di Nuzzo, Luigi, et al.
Publicado: (2015)

Fingolimod for Irradiation-Induced Neurodegeneration
por: Metzdorf, Judith, et al.
Publicado: (2019)

Interdisziplinäre Kommunikation: Augenarztbriefe an diabetologische Schwerpunktpraxen (DSP)
por: Stock, Lydia, et al.
Publicado: (2020)

A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo
por: Vermersch, Patrick, et al.
Publicado: (2017)

Using Machine Learning Algorithms for Identifying Gait Parameters Suitable to Evaluate Subtle Changes in Gait in People with Multiple Sclerosis
por: Trentzsch, Katrin, et al.
Publicado: (2021)

Cardiac ischemia and reperfusion in mice: a comprehensive hemodynamic, electrocardiographic and electrophysiological characterization
por: Clasen, Lukas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nugev9meni5rp0f975d1utucrb